Skip to content
Skip to navigation menu

 

Medicinal Chemistry Research Discipline

Medicinal Chemistry at the School of Pharmacy and Pharmaceutical Sciences


Design and synthesis of novel active compounds as drug candidates

(Coordinator, Andy Westwell )

Expertise includes: computer-based molecular graphics, synthesis and analysis of bioactive molecules, applying a wide variety of spectroscopic and other analytical methods. This research group enjoys well-equipped laboratories.  
There is close collaboration with virologists and biochemists throughout Europe and the USA.


Specialist Facilities: The Cardiff School of Pharmacy and Pharmaceutical Sciences has excellent facilities for Medicinal Chemistry. In 2005, we purchased a multi-nuclear Bruker 500MHz NMR spectrometer, and a Bruker micro TOF mass spectrometer (set up for Atmospheric Pressure Chemical Ionisation (APCI) and microspray). 
The synthetic chemistry laboratories are modern and each researcher has their own fumehood. 
We also have extensive molecular modelling hardware and software, as well as access to state of the art molecular graphics facilities within the University.

 

Current research interests include:
-
molecular modelling
- nucleotide prodrugs (“Protides”) especially as anticancer and antiviral agents

 

Latest News
Bruker Avance 500MHz multi-nuclear gradient NMR spectrometer
Warnings over so-called 'Legal highs'

06/01/2012

Dr Andy Westwell works in conjunction with WEDINOS to analyse unknown components of a number of 'legal highs'.

 

Andrew Lim awarded Commended Poster Prize at the 2011 UK PharmSci conference in Nottingham
Recognition for undergraduate pharmacy student at the UK PharmSci Conference

16/09/2011

Andrew Lim, who starts his final year in October, was awarded a Commended Poster Prize in Nottingham (Sept. 2011).

 

Prof McGuigan with the "Cardiff Inhibitex team" in the laboratory 2011
A major step forward for potential anti-Hepatitis C drug, INX-189, orginally synthesised in Cardiff

22/03/2011

A novel 'Pro Tide' drug, first synthesised in the Welsh School of Pharmacy less than 3 years ago, has been successfully tested in hepatitis C patients   by the U.S. biopharmaceutical company Inhibitex.

 

Presidents Scholars in Drug Discovery & development - group with speakers
President's Research Scholars in Drug Discovery & development report findings after 4 months

The six scholars present posters at the Entrepreneurship symposium.

 

Key outcome from phase II trial of FV-100, a potential anti-shingles drug
FV-100 shows promise as an anti-shingles drug from phase 2 clinical trial

14/12/2010

Results announced by Inhibitex  for their Phase 2 trial of FV-100, a drug developed by Professor Chris McGuigan at the Welsh School of Pharmacy.